Publications by authors named "Huan Wei Liang"
To compare the survival outcomes of patients with stage T2N0M0 esophageal cancer treated with surgery alone versus those treated with neoadjuvant chemoradiotherapy followed by surgery. Patients with stage T2N0M0 esophageal cancer, who either underwent surgery alone or received neoadjuvant chemoradiotherapy followed by surgery, were extracted from the Surveillance, Epidemiology, and End Results database covering the period from 2000 to 2020. Cancer-specific survival (CSS) and overall survival (OS) between the two treatment groups were compared.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how the number of examined lymph nodes (ELNs) affects survival outcomes in surgical patients with stage T1-2N0M0 small cell lung cancer (SCLC).
- Using data from the Surveillance, Epidemiology, and End Results database, researchers found that a threshold of 7 ELNs significantly predicts better cancer-specific survival (CSS) and overall survival (OS).
- Patients with fewer than 7 ELNs had substantially lower median CSS and OS compared to those with 7 or more, highlighting ELN count as an important factor in postoperative prognosis for this patient group.
Article Synopsis
- The study evaluates different treatment methods for stage T4b esophageal cancer by analyzing patient data from 2000 to 2020.
- A total of 482 patients were included, with various treatments showing differing cancer-specific survival (CSS) and overall survival (OS) rates, notably better outcomes for those who underwent surgery.
- The findings indicate that esophagectomy leads to significantly improved survival compared to chemoradiotherapy in these patients.
Article Synopsis
- A study analyzed survival outcomes in 445 patients with pT3N0M0 esophageal cancer who underwent surgery without prior chemoradiotherapy, using data from 2000 to 2020.
- Among patients with squamous cell carcinoma, various adjuvant treatments (chemoradiotherapy, chemotherapy, and radiotherapy) did not show significant survival benefits compared to surgery alone.
- Conversely, for those with adenocarcinoma, both adjuvant chemoradiotherapy and chemotherapy significantly improved overall survival compared to surgery alone, highlighting the varying effectiveness of treatments based on cancer type.
Article Synopsis
- The study assessed the effectiveness of combining immune checkpoint inhibitors (ICIs) with concurrent chemoradiotherapy (CCRT) versus using CCRT alone for treating locally advanced esophageal squamous cell carcinoma.
- A total of 101 patients participated, with results showing that while the combination therapy had a higher complete response rate (11.6% vs. 1.7%), it did not significantly improve progression-free survival or overall survival compared to CCRT alone.
- The findings also revealed differences in side effects, with CCRT alone causing more leukopenia, while the combination therapy led to a higher incidence of pneumonitis, highlighting the need for more research on these treatment options.
Article Synopsis
- * Analysis of data from the SEER database identified a lymph node ratio (LNR) of 0.29 as a critical threshold, indicating worse cancer-specific survival (CSS) and overall survival (OS) for patients with higher ratios.
- * Results showed that postoperative radiotherapy did not improve survival outcomes in high-risk patients (LNR ≥ 0.29), suggesting it may not be necessary for this group and highlighting the need for further research on alternative treatments.
Article Synopsis
- - The study aimed to evaluate various treatment approaches and survival outcomes for patients with stage T1-2N0M0 small cell lung cancer who had surgery, using data from 2000 to 2020.
- - A total of 190 patients were analyzed, with treatment options including surgery alone, surgery with chemotherapy, and surgery with chemoradiotherapy, finding that surgery + chemotherapy significantly improved overall survival (OS) compared to surgery alone.
- - The results showed median cancer-specific survival (CSS) was undetermined for surgery alone, while it was 123 and 113 months for the other groups, and highlighted that while chemotherapy benefited OS, adding radiotherapy did not enhance survival outcomes.
Article Synopsis
- A study was conducted to analyze treatment patterns and survival results for patients with unresectable Stage III EGFR-mutated non-small cell lung cancer (NSCLC) between 2012 and 2022.
- Out of 88 patients, most were treated with tyrosine kinase inhibitors (TKI), and comparisons showed that adding chemotherapy to TKI did not improve progression-free or overall survival outcomes.
- Ultimately, the findings indicated that combining chemotherapy with TKI did not provide better survival results than using TKI alone for these patients.
Article Synopsis
- Esophageal cancer is the sixth most common cancer globally, with about 50% of patients having advanced stages of the disease.
- Standard treatment for resectable cases involves neoadjuvant chemoradiotherapy followed by surgery, but many patients don't achieve complete responses and often have poor outcomes.
- The CheckMate 577 trial shows that nivolumab adjuvant therapy can improve disease-free survival for those not achieving a complete response, yet there are still unresolved clinical questions from the study's subgroup analyses that this review aims to address.
Fortifying Health Care Intellectual Property Transactions With Blockchain.
J Med Internet Res
August 2023
Article Synopsis
- Intellectual property (IP) is crucial for competition in healthcare, but the COVID-19 pandemic showed the importance of innovation through collaboration, revealing the need for a secure platform for IP sharing.* -
- This study proposes a blockchain-based framework to safeguard IP transactions in healthcare, supporting transparency and security while allowing for the sharing of advanced research technologies (ART).* -
- The framework encourages collaboration, reduces costs, and promotes public interest by providing incentive mechanisms like pledge tokens, but it requires leadership support and stakeholder participation for successful implementation.*
Article Synopsis
- - The study aimed to compare survival rates between unresectable stage III and stage IV patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated with first-line EGFR-TKI.
- - The analysis included 558 patients, revealing that stage III patients had better progression-free survival (PFS) but similar overall survival (OS) compared to stage IV patients both before and after propensity score matching (PSM).
- - Ultimately, the research concluded that while stage III patients had a higher median PFS, there was no significant difference in OS between the two stages when receiving EGFR-TKI treatment.
Article Synopsis
- - The study aimed to evaluate the effectiveness of combining EGFR-TKIs with antiangiogenic agents in treating non-small cell lung cancer patients with two specific genetic mutations: exon 19 deletion and exon 21 Leu858 Arg.
- - Researchers conducted a systematic review of five high-quality randomized control trials involving 1533 patients, analyzing their progression-free survival (PFS) with the combination treatment versus EGFR-TKI alone.
- - Results showed that the combination treatment improved PFS similarly for both mutation groups, indicating no significant difference in outcomes based on the type of genetic mutation (P=0.07, p=0.94).